# A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

> **NCT02323178** · PHASE1,PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 30 (actual)

## Conditions studied

- CMML
- Thrombocytopenia

## Interventions

- **DRUG:** eltrombopag

## Key facts

- **NCT ID:** NCT02323178
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-07
- **Primary completion:** 2018-12
- **Final completion:** 2021-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323178, "A Study of Eltrombopag in Patients With CMML and Thrombocytopenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02323178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*